Publications by authors named "Florian VoSS"

Claim this Profile
N
Nerandomilast in Patients with Progressive Pulmonary Fibrosis.
Toby M Maher, Shervin Assassi, Arata Azuma, Vincent Cottin, Anna-Maria Hoffmann-Vold, Florian Voss

N Engl J Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimating the effect of nintedanib on forced vital capacity in children and adolescents with fibrosing interstitial lung disease using a Bayesian dynamic borrowing approach.
Toby M Maher, Kevin K Brown, Steven Cunningham, Emily M DeBoer, Robin Deterding, Florian Voss

Pediatr Pulmonol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decline in forced vital capacity as a surrogate for mortality in patients with pulmonary fibrosis.
Toby M Maher, Susanne Stowasser, Florian Voss, Elisabeth Bendstrup, Michael Kreuter

Respirology· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD).
Toby M Maher, Shervin Assassi, Arata Azuma, Vincent Cottin, Anna-Maria Hoffmann-Vold, Florian Voss

BMJ Open Respir Res· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Physical Phantom for the Simulation of Neonatal Thermoregulation.
Florian Voss, Lennard Tiltmann, Simon Lyra, Steffen Leonhardt, Markus Lueken

Annu Int Conf IEEE Eng Med Biol Soc· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-modal body part segmentation of infants using deep learning.
Florian Voss, Noah Brechmann, Simon Lyra, Jöran Rixen, Steffen Leonhardt

Biomed Eng Online· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis.
Luca Richeldi, Arata Azuma, Vincent Cottin, Christian Hesslinger, Susanne Stowasser, Florian Voss

J Comp Eff Res· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Nintedanib on Progression of Systemic Sclerosis-Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial.
Shervin Assassi, Oliver Distler, Yannick Allanore, Takashi Ogura, John Varga, Florian Voss

ACR Open Rheumatol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular events and all-cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long-acting beta2-agonists.
Cristina Rebordosa, Dóra Körmendiné Farkas, Jukka Montonen, Kristina Laugesen, Florian Voss

Pharmacoepidemiol Drug Saf· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases.
Francesco Bonella, Vincent Cottin, Claudia Valenzuela, Marlies Wijsenbeek, Florian Voss

Adv Ther· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis.
Luca Richeldi, Arata Azuma, Vincent Cottin, Christian Hesslinger, Susanne Stowasser, Florian Voss

N Engl J Med· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Setup for Camera-Based Detection of Simulated Pathological States Using a Neonatal Phantom.
Florian Voss, Simon Lyra, Daniel Blase, Steffen Leonhardt, Markus Lüken

Sensors (Basel)· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The detailed clinical objectives approach to designing clinical trials and choosing estimands.
James Bell, Alan Hamilton, Oliver Sailer, Florian Voss

Pharm Stat· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Neonatal Phantom for Vital Signs Simulation.
Simon Lyra, Florian Voss, Andre Coenen, Daniel Blase, Idoia Badiola Aguirregomezcorta

IEEE Trans Biomed Circuits Syst· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)-estimation of adverse event risks.
Regina Stegherr, Claudia Schmoor, Jan Beyersmann, Kaspar Rufibach, Valentine Jehl, Florian Voss

Trials· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease.
Robin Deterding, Matthias Griese, Gail Deutsch, David Warburton, Emily M DeBoer, Florian Voss

ERJ Open Res· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial.
Klaus F Rabe, David M G Halpin, MeiLan K Han, Marc Miravitlles, Dave Singh

Respir Res· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses.
Heinz-Josef Lenz, Guillem Argiles, Takayuki Yoshino, Sara Lonardi, Alfredo Falcone, Florian Voss

Clin Colorectal Cancer· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of baseline symptom burden on treatment response in COPD.
Fernando J Martinez, Roger A Abrahams, Gary T Ferguson, Leif Bjermer, Lars Grönke

Int J Chron Obstruct Pulmon Dis· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose Determination for a Fixed-Dose Drug Combination: A Phase II Randomized Controlled Trial for Tiotropium/Olodaterol Versus Tiotropium in Patients with COPD.
François Maltais, Alan Hamilton, Florian Voß, M Reza Maleki-Yazdi

Adv Ther· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia.
Oliver G Ottmann, Carsten Müller-Tidow, Alwin Krämer, Richard F Schlenk, Michael Lübbert, Florian Voss

Br J Haematol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapies.
Steffen Unkel, Marjan Amiri, Norbert Benda, Jan Beyersmann, Dietrich Knoerzer, Florian Voss

Pharm Stat· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials.
Gary T Ferguson, Roland Buhl, Ulrich Bothner, Alberto de la Hoz, Florian Voß

Respir Med· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Î
β-Blockers in COPD: A Cohort Study From the TONADO Research Program.
François Maltais, Roland Buhl, Andrea Koch, Valeria C Amatto, Jim Reid

Chest· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat device for maintenance treatment of COPD: comparison with the long-acting β-agonist formoterol.
Andrea Koch, Henrik Watz, M Reza Maleki-Yazdi, Ulrich Bothner, Kay Tetzlaff

NPJ Prim Care Respir Med· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis